Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anacor Pharmaceuticals and Medicines for Malaria Venture (MMV) have widened their existing research pact to fund the clinical development of AN3661 to fight against malaria.
Subscribe to our email newsletter
The original agreement was signed in April 2010 to apply Anacor’s boron chemistry to identify new medicines to treat malaria.
As per the expanded agreement, MMV will provide additional funding to allow completion of the Phase 1 clinical trials and a human proof-of-concept study in malaria.
Anacor CEO David Perry said AN3661 appears to be acting through a novel mechanism of action, having shown potent activity against the Plasmodium falciparum parasites which are known to have resistance to a number of front-line antimalarial drugs.
"This orally delivered compound has demonstrated a remarkable safety and efficacy profile in preclinical studies and has the potential to become a novel and effective treatment for malaria," Perry said.